Terminal Access

Unlimited access to the most powerful analytical tools in finance.

Bloomberg Fair Value
20M Securities
50Y History
10Y Estimates
8.000+ News Daily
Subscribe for $2
Overview
Profile

Sophia Genetics stock

SOPH
CH1125843347
A3CVT8

Price

0
Today +/-
-0
Today %
-0 %

Sophia Genetics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Sophia Genetics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Sophia Genetics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Sophia Genetics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Sophia Genetics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Sophia Genetics Stock Price History

DateSophia Genetics Price
3/31/20250 undefined
3/28/20253.27 undefined
3/27/20253.73 undefined
3/26/20253.70 undefined
3/25/20253.12 undefined
3/24/20253.28 undefined
3/21/20253.02 undefined
3/19/20253.00 undefined
3/18/20253.00 undefined
3/17/20253.21 undefined
3/16/20253.20 undefined
3/13/20253.22 undefined
3/12/20253.12 undefined
3/11/20253.30 undefined
3/10/20253.09 undefined
3/9/20253.21 undefined
3/6/20253.24 undefined
3/5/20253.11 undefined
3/4/20253.11 undefined
3/3/20253.10 undefined
3/2/20253.57 undefined

Sophia Genetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sophia Genetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sophia Genetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sophia Genetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sophia Genetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sophia Genetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sophia Genetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sophia Genetics’s growth potential.

Sophia Genetics Revenue, EBIT and net profit per share

DateSophia Genetics RevenueSophia Genetics EBITSophia Genetics Net Income
2029e202.67 M undefined17.54 M undefined0 undefined
2028e153.1 M undefined-19.48 M undefined0 undefined
2027e120.62 M undefined-38.56 M undefined-36.13 M undefined
2026e95.86 M undefined-51.12 M undefined-48.91 M undefined
2025e76.01 M undefined-63.41 M undefined-59.13 M undefined
202465.17 M undefined-66.57 M undefined-62.49 M undefined
202362.37 M undefined-74.83 M undefined-78.98 M undefined
202247.56 M undefined-87.82 M undefined-87.45 M undefined
202140.45 M undefined-71.49 M undefined-73.68 M undefined
202028.4 M undefined-37.39 M undefined-39.34 M undefined
201925.36 M undefined-32.29 M undefined-33.79 M undefined

Sophia Genetics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
2019202020212022202320242025e2026e2027e2028e2029e
2528404762657695120153202
-12.0042.8617.5031.914.8416.9225.0026.3227.5032.03
68.0060.7162.5065.9667.7466.1556.5845.2635.8328.1021.29
17172531424300000
-33-39-73-87-78-62-59-48-3600
-18.1887.1819.18-10.34-20.51-4.84-18.64-25.00--
63.3463.3455.364.164.7566.0600000
-----------
Details

Keystats

ⓘ

Revenue and Growth

The Sophia Genetics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Sophia Genetics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
201920202021202220232024
           
18.497.3265.3178.6123.2580.23
7.96.46.36.613.567.44
1.20.30.81.31.651.25
3.63.45.75.26.485.87
2.72.34.84.63.114.62
33.8109.7282.9196.3148.0599.4
6.45.51621.423.119.38
000000
00004.744.24
2.44.77.411.818.1920.66
7.88.68.38.298.34
1.23.65.76.23.083.29
17.822.437.447.658.1155.9
51.6132.1320.3243.9206.16155.31
           
1.92.53.33.54.054.19
119.2227.4470.9471.6471.85472.24
-98.9-129.4-198.8-274.8-323.81-379.24
000000
000000
22.2100.5275.4200.3152.0997.19
4.44.55.85.84.624.56
6.18.814.513.117.4612.38
5.64.46.45.210.617.67
000000
3.23.91.82.72.932.19
19.321.628.526.835.6226.8
5.33.311.214.115.6727.84
000000
4.96.74.92.83.424.18
10.21016.116.919.0932.02
29.531.644.643.754.7158.82
51.7132.1320244206.8156.01
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Sophia Genetics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Sophia Genetics's financial health and stability.

Assets

Sophia Genetics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Sophia Genetics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Sophia Genetics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Sophia Genetics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
20192020202120222023
-33-41-73-87-78
12358
00000
-234-24
35162832
00000
00000
-31-31-57-70-48
-3-3-6-10-9
-3-24-56418
0-21-505217
00000
-2-1-4-2-3
110821600
-1107237-1-2
002500
00000
-3556118-31-38
-34.71-34.93-64.61-80.47-57.8
00000

Sophia Genetics stock margins

The Sophia Genetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sophia Genetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sophia Genetics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sophia Genetics's sales revenue. A higher gross margin percentage indicates that the Sophia Genetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sophia Genetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sophia Genetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sophia Genetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sophia Genetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sophia Genetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sophia Genetics Margin History

Sophia Genetics Gross marginSophia Genetics Profit marginSophia Genetics EBIT marginSophia Genetics Profit margin
2029e67.42 %8.66 %0 %
2028e67.42 %-12.73 %0 %
2027e67.42 %-31.96 %-29.95 %
2026e67.42 %-53.33 %-51.02 %
2025e67.42 %-83.42 %-77.8 %
202467.42 %-102.14 %-95.89 %
202368.8 %-119.97 %-126.63 %
202265.71 %-184.65 %-183.87 %
202162.35 %-176.74 %-182.15 %
202062.29 %-131.65 %-138.52 %
201970.31 %-127.33 %-133.24 %

Sophia Genetics Stock Sales Revenue, EBIT, Earnings per Share

The Sophia Genetics earnings per share therefore indicates how much revenue Sophia Genetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sophia Genetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sophia Genetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sophia Genetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sophia Genetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sophia Genetics Revenue, EBIT and net profit per share

DateSophia Genetics Sales per ShareSophia Genetics EBIT per shareSophia Genetics Earnings per Share
2029e3.03 undefined0 undefined0 undefined
2028e2.29 undefined0 undefined0 undefined
2027e1.8 undefined0 undefined-0.54 undefined
2026e1.43 undefined0 undefined-0.73 undefined
2025e1.14 undefined0 undefined-0.88 undefined
20240.99 undefined-1.01 undefined-0.95 undefined
20230.96 undefined-1.16 undefined-1.22 undefined
20220.74 undefined-1.37 undefined-1.36 undefined
20210.73 undefined-1.29 undefined-1.33 undefined
20200.45 undefined-0.59 undefined-0.62 undefined
20190.4 undefined-0.51 undefined-0.53 undefined

Sophia Genetics business model

Sophia Genetics SA is a Swiss company that was founded in 2011. The idea behind it was to improve genome sequencing and data analysis in order to make faster and more precise medical diagnoses. Sophia Genetics has since become a leading provider of artificial intelligence and data analysis in the medical field. The business model of Sophia Genetics is based on providing doctors and medical facilities with corresponding data analysis tools and platforms. Sophia Genetics' algorithms help to identify genetic anomalies and develop personalized therapies. This personalized medicine aims to improve healthcare. Sophia Genetics is divided into various sectors. The core sectors include oncology, pediatrics, cardiology, and neurology. In these specialized fields, Sophia Genetics' platforms and tools are used to optimize genome sequencing and data analysis, thus enabling faster and more precise diagnoses. The company offers a variety of products that help doctors and medical facilities create successful diagnoses and therapies. Sophia Genetics' flagship product is the Sophia Artificial Intelligence (AI) platform. This platform is used by doctors, clinics, and research institutions to analyze complex data and identify the genetic causes of diseases. The Sophia AI platform provides fast, precise, and secure genome sequencing and data analysis. Sophia Genetics also offers the Sophia DDM system. The DDM system is a cloud-based data exchange system that provides doctors and medical facilities with a secure way to exchange confidential medical data. The system also allows for the collection and analysis of information about diseases and disease progression in the population, in order to enable better healthcare. Another important product of Sophia Genetics is the Sophia Hereditary Cancer Solution. This product helps in the early detection of hereditary cancer. The Sophia Hereditary Cancer Solution provides fast and precise genetic diagnostics to identify family members at increased risk of cancer and take appropriate measures. Another product of Sophia Genetics is Sophia Radiomics. This software uses artificial intelligence and machine learning to detect and characterize diseases based on X-ray and CT scans. By analyzing large amounts of data, the Sophia Radiomics software can assist doctors in making more precise diagnoses and better treatment decisions. Sophia Genetics relies on close collaboration with medical facilities and research institutions worldwide. The company now has customers in over 60 countries and is a partner to more than 1,000 hospitals worldwide. Sophia Genetics' platforms and tools have already helped many people to be diagnosed and treated faster and more accurately. Overall, Sophia Genetics is an innovative company that has revolutionized medical diagnostics. With its advanced platforms and tools, the company provides doctors and medical facilities with an excellent opportunity to develop personalized therapies and enable better healthcare. Please write only the answer in the output. Sophia Genetics is one of the most popular companies on Eulerpool.com.

Sophia Genetics SWOT Analysis

Strengths

Sophia Genetics SA has several strengths that contribute to its success:

  • Advanced technology platform for genetic data analysis and interpretation
  • Wide range of genetic tests offered, covering various diseases and conditions
  • Strong network of partnerships with hospitals, laboratories, and research institutions
  • Well-established brand reputation in the genetic testing industry
  • Experienced and highly skilled team of geneticists and bioinformaticians

Weaknesses

Some weaknesses that Sophia Genetics SA needs to address:

  • Relatively high costs associated with genetic testing services
  • Limited market reach and presence in certain geographic regions
  • Dependence on external partners for sample collection and processing
  • Risk of potential data breaches or privacy concerns due to sensitive genetic information
  • Competition from other genetic testing companies and emerging technologies

Opportunities

There are several opportunities for Sophia Genetics SA to capitalize on:

  • Increasing demand for personalized medicine and precision healthcare
  • Growing adoption of genetic testing in research and clinical settings
  • Potential for expansion into untapped markets and collaborations with new partners
  • Advancements in genomic technologies, creating opportunities for innovation
  • Strategic acquisitions or alliances to enhance product offerings and market presence

Threats

Sophia Genetics SA faces several threats that may impact its growth:

  • Regulatory challenges and evolving legal frameworks for genetic testing
  • Emergence of competitors offering similar or alternative genetic testing solutions
  • Rapidly changing technologies and potential obsolescence of existing platforms
  • Public concerns over privacy and ethical implications of genetic testing
  • Economic downturn and reduced healthcare spending affecting market demand
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Sophia Genetics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Sophia Genetics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Sophia Genetics shares outstanding

The number of shares was Sophia Genetics in 2024 — This indicates how many shares 66.062 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sophia Genetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sophia Genetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sophia Genetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sophia Genetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Sophia Genetics.

Sophia Genetics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2024-0.23 -0.23  (-0.66 %)2024 Q4
9/30/2024-0.23 -0.28  (-19.35 %)2024 Q3
6/30/2024-0.29 -0.23  (20.17 %)2024 Q2
3/31/2024-0.28 -0.21  (24.68 %)2024 Q1
12/31/2023-0.28 -0.37  (-34.35 %)2023 Q4
9/30/2023-0.33 -0.21  (36.33 %)2023 Q3
6/30/2023-0.31 -0.33  (-5.6 %)2023 Q2
3/31/2023-0.32 -0.31  (3.94 %)2023 Q1
12/31/2022-0.37 -0.22  (40.38 %)2022 Q4
9/30/2022-0.39 -0.3  (22.6 %)2022 Q3
1
2

Sophia Genetics shareholders

%
Name
Stocks
Change
Date
10.46506 % Alychlo NV6,993,80002/15/2024
10.15945 % Generation Investment Management LLP6,789,560012/31/2024
7.38172 % aMoon Fund4,933,2051,722,3385/17/2023
5.03050 % Balderton Capital (UK) LLP3,361,8803,361,88012/31/2023
3.68110 % Camblong (Jurgi)2,460,081219,9412/15/2024
3.35664 % Banque Pictet & Cie S.A.2,243,240012/31/2024
3.34805 % Akre Capital Management, LLC2,237,504012/31/2024
3.31523 % UBS Asset Management Switzerland AG2,215,566-89212/31/2024
3.29193 % UBS Asset Management (Switzerland)2,200,0002,200,00012/31/2024
2.13728 % Principal Global Investors (Equity)1,428,344-26,79812/31/2024
1
2
3
4
5
...
10

Sophia Genetics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Amazon.com Stock
Amazon.com
SupplierCustomer0,760,870,440,65
Konica Minolta Stock
Konica Minolta
SupplierCustomer0,510,660,340,43
IDT B Stock
IDT B
SupplierCustomer0,270,450,710,86
PerkinElmer Stock
PerkinElmer
SupplierCustomer0,210,470,720,83
QIAGEN Stock
QIAGEN
SupplierCustomer0,060,400,170,69
Microsoft Stock
Microsoft
SupplierCustomer-0,080,220,350,78
General Electric Stock
General Electric
SupplierCustomer-0,200,800,750,69
Alphabet A Stock
Alphabet A
SupplierCustomer-0,210,860,560,76
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer-0,530,160,090,56
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,570,26-0,76-0,92
1

Most common questions regarding Sophia Genetics

What values and corporate philosophy does Sophia Genetics represent?

Sophia Genetics SA represents values of innovation, collaboration, and integrity in the field of genetic testing and analysis. The company believes in harnessing the power of data and technology to revolutionize healthcare delivery. Sophia Genetics SA's corporate philosophy is centered around democratizing genomics, making it accessible and affordable for all. By providing advanced solutions for genomic data analysis, the company aims to empower healthcare professionals in making informed decisions and improving patient outcomes. Sophia Genetics SA's commitment to accuracy, transparency, and continuous research drives its mission to transform the future of personalized medicine.

In which countries and regions is Sophia Genetics primarily present?

Sophia Genetics SA is primarily present in various countries and regions across the globe. Some of the key areas where the company has a significant presence include Europe, North America, Asia-Pacific, and the Middle East. With their advanced genomic data analysis solutions and services, Sophia Genetics SA has gained recognition and partnerships with renowned institutions, hospitals, and research centers in numerous countries. Their presence spans across multiple continents, making them a global leader in the field of genomics and personalized medicine.

What significant milestones has the company Sophia Genetics achieved?

Some significant milestones achieved by Sophia Genetics SA include securing a strategic partnership with Illumina, a global leader in DNA sequencing and array-based technologies. The company also expanded its genomic analysis platform to cover a wide range of genetic diseases, enabling more efficient and accurate diagnoses. Sophia Genetics SA has gained recognition by joining forces with renowned academic institutions and leading hospitals worldwide. Additionally, the company has received various prestigious awards, including being named a Global Cleantech prestigious 100 company. These achievements showcase Sophia Genetics SA's commitment to advancing genomic medicine and revolutionizing healthcare through innovative solutions and collaborations.

What is the history and background of the company Sophia Genetics?

Sophia Genetics SA is a leading healthtech company specializing in data-driven medicine and advanced genomic analysis. Founded in 2011 by Jurgi Camblong and Pierre Hutter, the company has since revolutionized the field of clinical genomics. Sophia Genetics uses artificial intelligence and machine learning to analyze patients' genomic data, providing accurate diagnoses and personalized treatment recommendations. With offices in Switzerland, the United States, and other countries, Sophia Genetics has collaborated with over 1,000 hospitals worldwide, improving patient care and outcomes. This company has quickly gained global recognition for its innovative solutions, which harness the power of genomics to transform healthcare.

Who are the main competitors of Sophia Genetics in the market?

The main competitors of Sophia Genetics SA in the market include companies such as Illumina, Thermo Fisher Scientific, and Qiagen.

In which industries is Sophia Genetics primarily active?

Sophia Genetics SA is primarily active in the healthcare and biotechnology industries.

What is the business model of Sophia Genetics?

The business model of Sophia Genetics SA is focused on providing advanced data analytics solutions for genomic testing. Sophia Genetics offers a cloud-based platform that utilizes artificial intelligence (AI) and machine learning algorithms to analyze genetic data and assist healthcare professionals in making more accurate diagnoses and treatment decisions. They collaborate with a wide network of medical laboratories worldwide, helping to improve the accessibility and efficiency of genomic testing. With their comprehensive suite of solutions, Sophia Genetics aims to drive precision medicine and enable personalized healthcare on a global scale.

What is the P/E ratio of Sophia Genetics 2025?

The P/E ratio cannot be calculated for Sophia Genetics at the moment.

What is the P/S ratio of Sophia Genetics 2025?

The P/S cannot be calculated for Sophia Genetics currently.

What is the Quality Investing of Sophia Genetics?

The Quality Investing for Sophia Genetics is 3/10.

What is the revenue of Sophia Genetics 2025?

The expected Sophia Genetics revenue is 76.01 M USD.

How high is the profit of Sophia Genetics 2025?

The expected Sophia Genetics profit is -59.13 M USD.

What is the business model of Sophia Genetics

Sophia Genetics SA is a Swiss company that specializes in providing advanced solutions for the analysis of genomic data. They work closely with leading hospitals and research institutions as part of their mission to improve healthcare. The business model of Sophia Genetics includes providing bioinformatics solutions to hospitals and clinics, using artificial intelligence and machine learning to improve clinical genomics and help doctors and researchers identify genetic anomalies and mutations faster and more accurately. Another important area of Sophia Genetics' business is collaboration with pharmaceutical companies in the development of personalized medicines. They collect and analyze data from patients with specific diseases to develop and test personalized treatment options. These partnerships also provide Sophia Genetics with access to large-scale studies and databases that provide more information about certain diseases. Sophia Genetics also offers a range of specialized products, including SOPHiA DDM, SOPHiA GENETICS Clinical Insights, SOPHiA AI Platform, and SOPHiA Solid Tumor Solution. SOPHiA DDM is a cloud-based platform that allows medical professionals and researchers to analyze genomic data and draw conclusions about diseases and treatment options. SOPHiA GENETICS Clinical Insights provides real-time interpretation support for the diagnosis and treatment of patients. SOPHiA AI Platform is an AI-based solution that helps interpret genomic data. SOPHiA Solid Tumor Solution is a diagnostic tool specialized in identifying genetic anomalies in tumor tissue samples. Sophia Genetics' technology is also applicable to a variety of industries, such as the agricultural industry. They collaborate with global biotechnology companies to develop new plant varieties and optimize agricultural processes. Over the years, Sophia Genetics has built numerous partnerships and collaborations with leading institutions and companies in the healthcare and bioinformatics industry. Their customers include hospitals, diagnostic laboratories, biorepositories, and pharmaceutical companies in Europe, North America, the Middle East, Africa, and Asia. In summary, the business model of Sophia Genetics SA is based on providing innovative bioinformatics solutions. They collaborate with leading institutions in the healthcare and bioinformatics industry and offer specialized products to improve the diagnosis and treatment of patients and develop personalized medicines. Their focus on collaboration with pharmaceutical companies and medical institutions, as well as the applicability of their technology to other industries, has made Sophia Genetics a key player in the journey towards personalized medicine.

What is the Sophia Genetics dividend?

Sophia Genetics pays a dividend of 0 USD distributed over payouts per year.

How often does Sophia Genetics pay dividends?

The dividend cannot currently be calculated for Sophia Genetics or the company does not pay out a dividend.

What is the Sophia Genetics ISIN?

The ISIN of Sophia Genetics is CH1125843347.

What is the Sophia Genetics WKN?

The WKN of Sophia Genetics is A3CVT8.

What is the Sophia Genetics ticker?

The ticker of Sophia Genetics is SOPH.

How much dividend does Sophia Genetics pay?

Over the past 12 months, Sophia Genetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sophia Genetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Sophia Genetics?

The current dividend yield of Sophia Genetics is .

When does Sophia Genetics pay dividends?

Sophia Genetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sophia Genetics?

Sophia Genetics paid dividends every year for the past 0 years.

What is the dividend of Sophia Genetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sophia Genetics located?

Sophia Genetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sophia Genetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sophia Genetics from 3/31/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/31/2025.

When did Sophia Genetics pay the last dividend?

The last dividend was paid out on 3/31/2025.

What was the dividend of Sophia Genetics in the year 2024?

In the year 2024, Sophia Genetics distributed 0 USD as dividends.

In which currency does Sophia Genetics pay out the dividend?

The dividends of Sophia Genetics are distributed in USD.

All fundamentals about Sophia Genetics

Our stock analysis for Sophia Genetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sophia Genetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.